Answer in brief
CVE-2026-123050 records a High severity (CVSS 7.1) vulnerability in Improper TLS Certificate Validation in Farmasimplex Healthcare Integration Modules. The current sources do not mark it as known exploited. The current feed maps CIPCarbone/Farmasimplex (generic). Check affected ranges and fixed versions before updating.
Analysis pending evidence review
HOL Guard separates source facts from reviewed analysis. See the methodology.
CVSS is 7.1. The current sources do not mark it as known exploited. Treat this as a source-backed prioritization signal, not a statement about your environment.
Analysis status
Analysis pending evidence review
Factual feed record only; HOL analysis is not approved for indexing. Read the methodology.
The current feed maps CIPCarbone/Farmasimplex (generic). Check affected ranges and fixed versions before updating.
| Package | Affected range | Fixed version |
|---|---|---|
| CIPCarbone/Farmasimplexgeneric | >=0 <16.2.0 | 16.2.0 |
Published upstream
Nov 17, 2026
Evidence: source:cvelist:source_dates:source-dates:recordSource modified
Nov 17, 2026
Evidence: source:cvelist:source_dates:source-dates:recordFirst seen by HOL
Nov 17, 2026
Multiple Farmasimplex healthcare integration modules do not properly validate TLS certificates, allowing an attacker who can intercept network traffic to impersonate trusted healthcare services and perform man-in-the-middle attacks, potentially leading to disclosure or modification of sensitive data.
Quoted source text, attributed separately from HOL analysis.